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A Preliminary Randomized Open Labeled Comparative
Analysis of Efficacy & Safety of Inhaled Tiotropium and
Tiotropium Plus Formoterol in COPD
Muzaffer Ahmad Pukhta, Zubair Ahmad Ashai, Mushtaq Ahmad Shah, Zaffar Abbas,
Samina Farhat, Shakeel Ahmad Mir, Z. Singh,Vishal R. Tandon
A randomized, open labeled comparative analysis for 2-week therapy of inhaled Tiotropium (T) (n=30) and
Tiotropium plus Formoterol (TF) (n=30) once daily was carried in stable COPD patients. Objective
parameters like lung functions (FEV1 and FVC), SBP, DBP, pulse and subjective parameters like
improvement in respiratory symptoms & safety were assessed at baseline and after 2 weeks of treatment.
Mean FEV1 was 1.0963±0.3826 & 1.1657±0.3701 as well as 1.1227±0.4129 & 1.2260±0.3830 before &
after treatment with inhaled T & TF respectively. A statistically significant p<0.05 and p<0.001 improvement
was only observed for FEV1 without significantly affecting other study parameters with two treatment
modalities respectively when analyzed from respective base lines. However, on comparing the post drug
improvement in objective & subjective parameters  among T & TF treatment arms showed statistically
insignificant p>0.05 variation. Both the regimens were well tolerated and no case warranted withdrawal of
treatment. The present study suggests that in the treatment of COPD, inhaled long acting bronchodilators
(T & TF) on comparison appear equally effective & safe.
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       Abstract
COPD  is a most common disease affecting many
people worldwide. It is a 4th leading cause of death
worldwide. Globally by 2020 it is projected to rise to 3rd
position as a cause of death. Worldwide Prevalence of
COPD ranges from 4-6%(1).India Prevalence is
documented  up to 4.1 %  with  Male(5%) & Female
(3.2%)(2). Study  from Kashmir pointed to a higher
prevalence of 7.55% in smokers and 10.56% in people
living in poorly ventilated houses (3). Overall COPD
imposes a great  socioeconomic burden. Among the
various bronchodilators available, the long acting
bronchodilators are the first choice option for the treatment
of stable COPD (4).  Presently, two types of inhaled
long-acting bronchodilators are available for clinical use:
the long-acting beta-2 agonists (LABAs) Formoterol and
Salmeterol and the new long-acting anticholinergic
Tiotropium(5).It has been demonstrated that the
combination of the short-acting beta-2 agonist Salbutamol
with the short-acting anticholinergic Ipratropium is
superior to either single agent alone (6)  as such  one can
expect that combination therapy with the long-acting drugs
may achieve even greater benefit. Limited clinical data
on combination therapy of Tiotropium and an inhaled long
acting beta-2 agonist Formoterol in COPD has promted
us to study the effect of add on therapy of Formoterol on
efficacy and tolerability in patients with stable COPD on
Tiotropium.
 Materials and Methods
The study was conducted at chest diseases hospital
Srinagar and was a randomized, open labeled study design
with 2-week treatment periods (Fig 1 ). Approval from
the hospital medical ethics committee and written
informed consent from patients were obtained before
medication washout or any study procedure. Patients
having a clinical diagnosis of COPD according to the
American Thoracic Society (ATS) criteria were selected
(7). The patients had to show a stable airways obstruction
with FEV1 < 60% of predicted, and an FEV1/FVC ratio
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< 70% (8). The patients had to be at least 40 years old,
and all had to be current or previous smokers (>10 pack-
years).The excluion criteria of the study shown in Fig 1
from the study.
After initial screening (visit 1), patients returned for a
second clinic visit (visit 2) and base line investigations
and FVC and FEV1  were measured. Long-acting
inhaled beta-2 agonists were not allowed for at least 48
h, and short-acting anticholinergics or beta-2 agonists for
at least 8 h before the second visit and the spirometric
baseline measurements. While performing the FVC
maneuver a cough, an inspiration, a Valsalva maneuver,
a leak, or an obstructed mouth piece disqualified the trial
and the test was repeated. The patients entered a 2-
week pretreatment period of T, 18 μg qd inhalation powder
in order to achieve a pharmacodynamic steady state of
T (9) Subsequently, treatment with T 18 μg qd  in the
morning to one group (R1)  and Tiotropium 18 μg qd  plus
Formoterol 12 μg once daily dry powder inhalation capsule
in the morning to the second group (R2)  were given.
The patients returned for clinical examination at an
interval of one week during the study period. During this
visit they were asked about the change in symptoms and
about any adverse drug effects.  Adverse events were
recorded and monitored throughout the study. An adverse
event was defined as any symptom, physical sign,
syndrome, or disease that occurred after start of treatment
with the study drug or was present at the start of
treatment with the study drug and worsened. Patients
underwent a physical examination at the screening visit
and at each subsequent visit. Blood pressure and heart
rate were also recorded (10). At the end of 2 weeks the
post-drug spirometry was performed after the study
medication was inhaled in the presence and under the
supervision of the trial physician, keeping the pulmonary
technician blinded for the inhaled medication.
Furthermore, the patients did not communicate to the
pulmonary technician which study medication was
inhaled. The Spirometer used during the study was PC
based RM Medispiror, manufactured by Recorders &
Medicare Systems Chandigarh. The spirometer fulfilled
ATS criteria for accuracy and precision. The Spirometry
testing was performed according to the guidelines
prescribed in the America Thoracic Society (ATS)
guidelines (11). For conducting the Spirometry the open
circuit method was used.
Measurement
The objective evaluation of the effectiveness was done
by evaluating the improvement in the various spirometric
values like FVC and FEV1(12). Subjective evaluation of
effectiveness was done by asking the patient about the
change in symptoms of cough and breathlessness. The
patients were graded into the following three categories
according to the change in symptomatology i.e. Improved
(I) No Change(NC) and Worse(W) (13,14). The objective
assessment of the tolerability was done by noting the change
in pulse and B.P .Subjective assessment of the tolerability
was done by noting various side effects (15).
Statistical Evaluation
Statistical evaluations were accomplished with paired
t tests for before and after treatment results of  R1 and
R2, while ANOVA was used for comparing after
treatment results of  R1 and R2. Chi square test was
used for evaluating the subjective improvement as well
as adverse effects reported by patients of R1 and R2.
Continuous data is reported as mean±standard deviation.
A p value of <0.05 was considered significant and a p
value of <0.001 was considered highly significant. Data
from patients withdrawn early were included in the
analyses up to the time of study discontinuation. No
interpolation was used for the missed data. The primary
efficacy endpoint was FEV1   response at the end of the
2-week treatment period. FEV1   response was defined
as the change from baseline at the end of the 2 week
treatment. Baseline FEV1   was the pre-treatment FEV1
measured at Visit 2, 10 minutes prior to administration of
the first dose of the study medication.
Results
A total of 81 patients were screened; 60 of them were
eligible according to ATS criteria and entered the study.
Of the 60 randomized patients, 58 completed the study
and 2 discontinued prematurely as they did not report for
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post drug spirometry. The demographic profile and base
line characteristics of the study population are
shown in table 1.
Objective parameters like lung functions (FEV1 and
FVC), SBP, DBP, pulse and subjective parameters like
improvement in respiratory symptoms & safety were
assessed at baseline and after 2 weeks of treatment.
Mean FEV1 was 1.0963±0.3826 & 1.1657±0.3701 as
well as 1.1227±0.4129 & 1.2260±0.3830 before & after
treatment with inhaled T & TF respectively. A statistically
significant p<0.05 and p<0.001 improvement was only
observed for FEV1 without significantly affecting other
study parameters with two treatment modalities
respectively when analyzed from respective base lines.
However, on comparing the post drug improvement in
objective & subjective parameters  among T & TF
treatment arms showed statistically insignificant p>0.05
variation.  Both the regimens were, however, well tolerated
as no case warranted withdrawal of treatment.
The effect of two regimens on various study
parameters are shown in table 2  & 3 and Fig 2.
Discussion
The long-acting bronchodilators are more effective and
convenient than short-acting bronchodilators. It is also
emphasized that combining bronchodilators may improve
efficacy without increasing the risk of side effects
compared to increasing the dose of a single bronchodilator
(16).Inhaled anticholinergic drugs are often recommended
for use as a first-line therapy for patients with COPD
because they provide similar or more effective
bronchodilating actions, as well as fewer side effects as
compared to other bronchodilators (17). The use of T is
a safe and effective once-daily anticholinergic
bronchodilator and is useful as first-line therapy in COPD
(18).A significant body of evidence supports the use of
long-acting beta-2 agonists and anticholinergic agents in
reducing exacerbations in patients with moderate to severe
COPD (19).
The present study investigated the additional effects
of Formoterol once daily inhaled in patients receiving T.
Our results showed a statistically significant improvement
in FEV1 with both the regimens but the improvement
with regimen R2 was highly significant (p<.001).These
results correlate well with other studies which also found
a significant improvement in FEV1 and FVC with T and
TF. The improvement in FEV1 was higher on addition of
Formoterol to Tiotropium (16).   Same results were shown
by other studies (20,21).  Various studies  have  shown
that in patients with COPD a significant improvement in
FEV1  occurs after treatment with T (16,22,23).
Bronchodilators may increase FEV1, FVC or exercise
tolerance, but an increase in FEV1 does not correlate
Table 1. Demographic Characteristics of Study Population
Table 2. Comparative Effects of R1 & R2 on Objective
                Parameters
Chi Square Test (x2 = 0.165 and p > 0.05)
80%
93.33%
10% 10%
3.33% 3.33%
Fig  2.   Comparative Effects of R1 & R2 on Subjective
                Symptoms
Side  Effects 
n(%)
R1 R2
Dry mouth 8(26.66) 7(23.33)
Headache 3(10) 3(10)
Dizziness 1(3.33) (0)
Tremor (0) 2(6.66)
Palpitations (0) 1(3.33)
Total  12(40) 13(43.33)
Table  3.   Adverse  Effects of R1 & R2
well with an improvement in symptoms (24). In our study
the improvement in FEV1 and percentage improvement
(Fig-2) in respiratory symptoms correlated well in both
the regimens. However, the improvement in
symptomatology was statistically insignificant (x2=0.165,JK SCIENCE
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p>0.05).The objective tolerability of the two regimens in
the present study revealed that both regimens caused
statistically insignificant changes in vital signs viz. pulse
rate, systolic blood pressure and diastolic blood pressure.
(Table 2) These findings corroborated well with the
finding of other studies on TF (16,10).  Regarding the
safety, various other studies also showed almost same
percentage of side effects with these drugs (13,15,25) as
shown by current study. The results of the present study
need to be substantiated with long-term studies to
establish whether the improvements in lung function
translate into improvements in clinical outcomes such as
symptom scores, health status, exercise tolerance,
exacerbation rates and the long term safety profile which
have been the limitations of the present study.
Conclusion
The present study suggests that in the treatment of
COPD, inhaled long acting bronchodilators (T & TF) on
comparison appear equally effective & safe. Thereby,
suggesting no advantage of adding Formoterol to
Tiotropium
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